View Expired Tender

Get immediate access to tenders like the one below by subscribing now to Tenders Direct. We will set up your personalised profile and send you tender alerts direct to your mailbox as soon as they are published. You will also benefit from having access to historical tenders.

  • Notice Summary
    UK-Southampton: 19/29 Frequency of Blood Tests for Inflammatory Conditions
    GB003ZM293891
    National Institute for Health Research (NIHR)
    19 April 2019
    25 September 2019
    Contract Notice - Other
  • Notice Abstract

    19/29 Frequency of blood tests for inflammatory conditions Rationale: Common inflammatory conditions including rheumatoid arthritis, inflammatory bowel disease and the spondyloarthritides, are commonly treated with immunosuppressive drugs, such as disease-modifying anti-rheumatic drugs (DMARDs). Many of these disease-modifying drugs carry a risk of adverse events (e.g. hepatotoxicity) and thus require careful monitoring with the use of blood tests such as full blood count, liver function tests and urea and electrolyte tests. For this patient group there is uncertainty as to the optimum frequency of monitoring. Evidence suggests that for a large majority of people using these drugs, adverse events are very unlikely and the monitoring regimen itself may represent a greater burden. Testing too often is costly and places significant burden on the patient and the healthcare system, but not testing often enough could increase the risk of adverse events occurring. In recent years, this routine testing has moved into primary care. Drug manufacturers and medical guidelines provide advice on the frequency of testing (NICE guidance recommends regular blood monitoring, generally every 3 months) but these may not be strictly followed. Therefore, the HTA programme wishes to commission research to determine the optimum strategy for the frequency of routine blood testing for patients with inflammatory conditions taking long-term immunosuppressive medication.

  • Notice Details

    CONTRACT NOTICE – NATIONAL

    SERVICES

    1 Authority Details

    1.1

    Authority Name and Address


    National Institute for Health Research (NIHR)

    N/A

    Southampton


    UK

    N/A

    N/A


    N/A

    1.2

    Address from which documentation may be obtained

    As in 1.1

    1.3

    Completed documents must be returned to:

    As in 1.1

    2 Contract Details

    2.1

    Title

    19/29 Frequency of Blood Tests for Inflammatory Conditions

    2.2

    Description of the goods or services required

    19/29 Frequency of blood tests for inflammatory conditions

    Rationale:

    Common inflammatory conditions including rheumatoid arthritis, inflammatory bowel disease and the spondyloarthritides, are commonly treated with immunosuppressive drugs, such as disease-modifying anti-rheumatic drugs (DMARDs).

    Many of these disease-modifying drugs carry a risk of adverse events (e.g. hepatotoxicity) and thus require careful monitoring with the use of blood tests such as full blood count, liver function tests and urea and electrolyte tests. For this patient group there is uncertainty as to the optimum frequency of monitoring. Evidence suggests that for a large majority of people using these drugs, adverse events are very unlikely and the monitoring regimen itself may represent a greater burden. Testing too often is costly and places significant burden on the patient and the healthcare system, but not testing often enough could increase the risk of adverse events occurring. In recent years, this routine testing has moved into primary care. Drug manufacturers and medical guidelines provide advice on the frequency of testing (NICE guidance recommends regular blood monitoring, generally every 3 months) but these may not be strictly followed.

    Therefore, the HTA programme wishes to commission research to determine the optimum strategy for the frequency of routine blood testing for patients with inflammatory conditions taking long-term immunosuppressive medication.

    2.3

    Notice Coding and Classification

    2.4

    Total quantity or scope of tender

    3 Conditions for Participation

    3.1

    Minimum standards and qualification required

    4 Administrative Information

    4.1

    Type of Procedure

    The procedure type is unknown.

    4.2

    Reference number attributed to the notice by the contracting authority

    19/29

    4.3

    Time Limits

       25-09-2019  Time 13:00

    4.5

    Language or languages in which tenders or requests to participate can be drawn up

    EN 

    4.6

    Tender Submission Postbox

    5 Other Information

    5.1

    Additional Information

    Please visit the following portal to view this notice:

    https://www.nihr.ac.uk/funding-and-support/funding-opportunities/1929-frequency-of-blood-tests-for-inflammatory-conditions/10557

    The deadline for applications is 1pm, 25 September 2019.

    (MT Ref:293891)

    5.2

    Additional Documentation

    5.3

    Publication date of this notice

     19-04-2019